Moisés Selman,¹ R Gisli Jenkins,² Eric S White,³ Vincent Cottin,⁴ Yasuhiko Nishioka,⁵ Imre Noth,⁶ Antje Prasse,⁷ Jin Woo Song,⁸ Benjamin Strobel,⁹ German Leparc,⁹ Carina Ittrich,⁹ Claudia Diefenbach,¹⁰ Klaus B Rohr,¹⁰ Susanne Stowasser,¹⁰ Toby M Maher¹¹ on behalf of the INMARK trial investigators

¹Instituto Nacional de Enfermedades Respiratorias “Ismael Cosio Villegas”, Mexico City, Mexico; ²National Institute for Health Research Respiratory Biomedical Research Centre, City Campus, Nottingham University Hospital, Nottingham, UK; ³University of Michigan, Division of Pulmonary and Critical Care Medicine, Ann Arbor, Michigan, USA; ⁴Respiratory Diseases Department, National Reference Center for Rare Pulmonary Diseases, Respiratory Diseases Department, Louis Pradel Hospital, Claude Bernard Lyon 1 University, Lyon, France; ⁵Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan; ⁶Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia, USA; ⁷MHH Hannover Medical School, Department of Respiratory Medicine, Hannover, Germany; ⁸University of Ulsan College of Medicine, Asan Medical Center, Pulmonary and Critical Care Medicine, Seoul, South Korea; ⁹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; ¹¹National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK